IL149364A0 - Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 - Google Patents
Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23Info
- Publication number
- IL149364A0 IL149364A0 IL14936400A IL14936400A IL149364A0 IL 149364 A0 IL149364 A0 IL 149364A0 IL 14936400 A IL14936400 A IL 14936400A IL 14936400 A IL14936400 A IL 14936400A IL 149364 A0 IL149364 A0 IL 149364A0
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- formation
- acid derivative
- hydroxamic acid
- soluble human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9925470.8A GB9925470D0 (en) | 1999-10-27 | 1999-10-27 | Novel compounds |
| PCT/EP2000/010649 WO2001030747A1 (en) | 1999-10-27 | 2000-10-25 | Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL149364A0 true IL149364A0 (en) | 2002-11-10 |
Family
ID=10863507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14936400A IL149364A0 (en) | 1999-10-27 | 2000-10-25 | Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6673965B1 (xx) |
| EP (1) | EP1224164B1 (xx) |
| JP (1) | JP3922431B2 (xx) |
| KR (1) | KR20020044578A (xx) |
| CN (1) | CN1182107C (xx) |
| AR (1) | AR026244A1 (xx) |
| AT (1) | ATE284382T1 (xx) |
| AU (1) | AU766072B2 (xx) |
| BR (1) | BR0015082A (xx) |
| CA (1) | CA2389319A1 (xx) |
| CO (1) | CO5261576A1 (xx) |
| CZ (1) | CZ20021424A3 (xx) |
| DE (1) | DE60016622T2 (xx) |
| DK (1) | DK1224164T3 (xx) |
| ES (1) | ES2233474T3 (xx) |
| GB (1) | GB9925470D0 (xx) |
| GC (1) | GC0000142A (xx) |
| HK (1) | HK1049146A1 (xx) |
| HU (1) | HUP0203270A3 (xx) |
| IL (1) | IL149364A0 (xx) |
| MX (1) | MXPA02004228A (xx) |
| MY (1) | MY133601A (xx) |
| NO (1) | NO20021965L (xx) |
| NZ (1) | NZ518566A (xx) |
| PE (1) | PE20010898A1 (xx) |
| PL (1) | PL356524A1 (xx) |
| PT (1) | PT1224164E (xx) |
| SI (1) | SI1224164T1 (xx) |
| TW (1) | TW561141B (xx) |
| UY (1) | UY26416A1 (xx) |
| WO (1) | WO2001030747A1 (xx) |
| ZA (1) | ZA200203255B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2334636A2 (en) * | 2008-09-19 | 2011-06-22 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| US8945575B2 (en) | 2009-12-01 | 2015-02-03 | Trustees Of Boston University | Treatment of IgE-mediated disease |
| WO2011073845A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
| CN104529883A (zh) | 2011-03-07 | 2015-04-22 | 辉瑞大药厂 | 可用作抗菌剂的氟吡啶酮衍生物 |
| AU2012238374B2 (en) | 2011-04-08 | 2015-04-02 | Pfizer Inc. | Isoxazole derivatives useful as antibacterial agents |
| CN103492368A (zh) | 2011-04-08 | 2014-01-01 | 辉瑞大药厂 | 用作抗菌剂的咪唑、吡唑和噻唑衍生物 |
| EP2525213A1 (en) * | 2011-05-16 | 2012-11-21 | Renishaw plc | Spectroscopic apparatus and methods for determining components present in a sample |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9513331D0 (en) | 1995-06-30 | 1995-09-06 | British Biotech Pharm | Matrix metalloproteinase inhibitors |
| GB9813451D0 (en) * | 1998-06-22 | 1998-08-19 | Smithkline Beecham Plc | Novel compounds |
-
1999
- 1999-10-27 GB GBGB9925470.8A patent/GB9925470D0/en not_active Ceased
-
2000
- 2000-10-25 BR BR0015082-7A patent/BR0015082A/pt not_active IP Right Cessation
- 2000-10-25 SI SI200030603T patent/SI1224164T1/xx unknown
- 2000-10-25 MY MYPI20005012A patent/MY133601A/en unknown
- 2000-10-25 ES ES00975954T patent/ES2233474T3/es not_active Expired - Lifetime
- 2000-10-25 WO PCT/EP2000/010649 patent/WO2001030747A1/en active IP Right Grant
- 2000-10-25 UY UY26416A patent/UY26416A1/es not_active Application Discontinuation
- 2000-10-25 MX MXPA02004228A patent/MXPA02004228A/es active IP Right Grant
- 2000-10-25 EP EP00975954A patent/EP1224164B1/en not_active Expired - Lifetime
- 2000-10-25 GC GCP2000972 patent/GC0000142A/xx active
- 2000-10-25 NZ NZ518566A patent/NZ518566A/en unknown
- 2000-10-25 AT AT00975954T patent/ATE284382T1/de not_active IP Right Cessation
- 2000-10-25 DK DK00975954T patent/DK1224164T3/da active
- 2000-10-25 AR ARP000105622A patent/AR026244A1/es not_active Application Discontinuation
- 2000-10-25 DE DE60016622T patent/DE60016622T2/de not_active Expired - Lifetime
- 2000-10-25 IL IL14936400A patent/IL149364A0/xx unknown
- 2000-10-25 CZ CZ20021424A patent/CZ20021424A3/cs unknown
- 2000-10-25 AU AU13895/01A patent/AU766072B2/en not_active Ceased
- 2000-10-25 HU HU0203270A patent/HUP0203270A3/hu unknown
- 2000-10-25 CN CNB008173680A patent/CN1182107C/zh not_active Expired - Fee Related
- 2000-10-25 CA CA002389319A patent/CA2389319A1/en not_active Abandoned
- 2000-10-25 PT PT00975954T patent/PT1224164E/pt unknown
- 2000-10-25 US US10/111,209 patent/US6673965B1/en not_active Expired - Fee Related
- 2000-10-25 JP JP2001533102A patent/JP3922431B2/ja not_active Expired - Fee Related
- 2000-10-25 KR KR1020027005340A patent/KR20020044578A/ko not_active Application Discontinuation
- 2000-10-25 PL PL00356524A patent/PL356524A1/xx unknown
- 2000-10-26 TW TW089122497A patent/TW561141B/zh active
- 2000-10-26 CO CO00081571A patent/CO5261576A1/es not_active Application Discontinuation
- 2000-10-27 PE PE2000001156A patent/PE20010898A1/es not_active Application Discontinuation
-
2002
- 2002-04-24 ZA ZA200203255A patent/ZA200203255B/en unknown
- 2002-04-25 NO NO20021965A patent/NO20021965L/no unknown
- 2002-12-19 HK HK02109235A patent/HK1049146A1/xx not_active IP Right Cessation
-
2003
- 2003-10-03 US US10/678,679 patent/US20040077727A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL335027A1 (en) | Derivatives of arylsulphonylamino hydroxamic acid | |
| HUP0101793A3 (en) | Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase | |
| IL148670A0 (en) | Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties | |
| IL147216A0 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives | |
| AU2002220735A1 (en) | Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain | |
| IL149364A0 (en) | Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 | |
| HUP0103788A3 (en) | Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives | |
| HK1045260B (zh) | 15-羥基二十碳四烯酸雜原子阻斷類似物及其使用方法 | |
| GB9929979D0 (en) | Hydroxamic acid derivatives | |
| GB2355657B (en) | Inhibitors Of Gastric Acid Secretion | |
| HK1025894A1 (en) | Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release. | |
| AU7653600A (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis | |
| GB9907082D0 (en) | The preparation of carboxylic acid derivatives | |
| AU4021700A (en) | Methods of use of beta1-integrin inhibitors | |
| AU4332900A (en) | Use of interleukin-11 to treat gastrointestinal disorders | |
| AU2002218512A1 (en) | Compound of hydroxamic acid derivative and hyaluronic acid | |
| AU2001289723A1 (en) | Novel use of difluoromalonic acid esters | |
| AU1872001A (en) | Hydroxamic acid derivatives as inhibitors of human cd23 and of the tnf release | |
| AU7951600A (en) | Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase | |
| PL332532A1 (en) | Method of obatining 4-amino-5-hexenic acid | |
| GB0109553D0 (en) | Hydroxamic acid derivatives | |
| GB0110770D0 (en) | Hydroxamic acid derivatives | |
| GB0107361D0 (en) | Hydroxamic acid derivatives | |
| GB0109554D0 (en) | Hydroxamic acid derivatives | |
| GB0109551D0 (en) | Hydroxamic acid derivatives |